Canine Cognitive Dysfunction (CCD), Alzheimer’s Disease (AD), and β-Amyloid Accumulation: Using CCD as a Reference for the Development of AD Treatments and Therapies

Isabel (Izzi) Gibbs, Mary Boyes, Honors College, Virginia Commonwealth University, 701 West Grace Street, Richmond, VA 23284-3010

Alzheimer’s Disease (AD) is a growing epidemic, with a new development of the disease occurring every 65 seconds (Alzheimer’s Association, n.d.). Canine Cognitive Dysfunction (CCD) is a disease with symptoms and progression patterns that parallels AD. I studied how β-Amyloid  accumulates in brain regions—such as the prefrontal, occipital, entorhinal and parietal cortices—in canines to determine how β-amyloid accumulation is associated with the development of behaviors signifying cognitive decline observed in CCD and AD—such as changes in the sleep-wake cycle, social interaction, housetraining, and general orientation—in order to understand how neuroscientists may be able to derive new understandings from a canine model with CCD, and apply them to humans with AD to develop therapies and treatments for AD. To capture a variety of perspectives when researching CCD and AD, I developed a list of questions to help guide and focus my research, with my main question being how the shared pathologies in canines and humans allow for the application of CCD treatment on AD. Through my research I discovered that domestic canines and humans share the same environmental stressors, develop oxidative stress in a similar manner, and β-amyloid accumulation in the canine brain parallels β-amyloid accumulation in the human brain. Additionally, canine response to pharmaceuticals mimics human response to pharmaceuticals, and that conducting studies on domestic canines with CCD may be the best animal model for AD. I surmise that future research should be conducted through testing how known CCD treatments (with varying active ingredients and constituents) work to suppress β-amyloid accumulation in humans. Treatments previously found to be successful on canines with CCD should be restudied for the purpose of observing how the treatment interacts with canine pathology that is shared with humans in order to better determine how CCD treatments can be manipulated to be efficient in treating AD. 

Additional Abstract Information

Presenter: Isabel (Izzi) Gibbs

Institution: Virginia Commonwealth University

Type: Poster

Subject: Animal Sciences

Status: Approved

Time and Location

Session: Poster 1
Date/Time: Mon 1:30pm-2:30pm
Session Number: 2017